RHYTHM PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | ||
|---|---|---|
| | RHYTHM PHARMACEUTICALS, INC. | |
| | | |
| | By: | /s/ David P. Meeker M.D. |
| | | David P. Meeker M.D. |
| | | President and Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| | | | |||
| Name | Title | | Date | ||
|---|---|---|---|---|---|
| | | | | | |
| /s/ David P. Meeker M.D. | | Chief Executive Officer, Director, Chairman of the Board | | | February 29, 2024 |
| David P. Meeker M.D. | | (Principal Executive Officer) | | | |
| | | | | | |
| /s/ Hunter Smith | | Chief Financial Officer | | | February 29, 2024 |
| Hunter Smith | | (Principal Financial Officer) | | | |
| | | | | | |
| /s/ Christopher P. German | | Corporate Controller | | | February 29, 2024 |
| Christopher P. German | | (Principal Accounting Officer) | | | |
| | | | | | |
| /s/ Edward T. Mathers | | Lead Director | | | February 29, 2024 |
| Edward T. Mathers | | | | | |
| | | | | | |
| /s/ Stuart Arbuckle | | Director | | | February 29, 2024 |
| Stuart Arbuckle | | | | | |
| | | | | | |
| /s/ Camille L. Bedrosian, M.D. | | Director | | | February 29, 2024 |
| Camille L. Bedrosian M.D. | | | | | |
| | | | | | |
| /s/ Jennifer L. Good | | Director | | | February 29, 2024 |
| Jennifer L. Good | | | | | |
| | | | | | |
| /s/ Christophe R. Jean | | Director | | | February 29, 2024 |
| Christophe R. Jean | | | | | |
| | | | | | |
| /s/ David W. J. McGirr | | Director | | | February 29, 2024 |
| David W. J. McGirr | | | | | |
| | | | | | |
| /s/ Lynn A. Tetrault | | Director | | | February 29, 2024 |
| Lynn A. Tetrault | | | | | |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| | |
|---|---|
| | Page No. |
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 42) | F-2 |
| | |
| Audited Consolidated Financial Statements: | |
| Consolidated Balance Sheets | F-4 |
| Consolidated Statements of Operations and Comprehensive Loss | F-5 |
| Consolidated Statements of Stockholders’ Equity | F-6 |
| Consolidated Statements of Cash Flows | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.